Jiangsu Alphamab Biopharmaceuticals Co., Ltd

This early-stage study tests a new drug called JSKN016HC in about 42 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also watch for any signs that the drug shrinks…

This study tests a new combination of two drugs (JSKN016 and D-0502) in 60 people with advanced hormone receptor-positive, HER2-negative breast cancer that has worsened after standard hormone therapy. The goal is to see if the combo is safe and shrinks tumors. Participants receiv…

This study tests a new drug called JSKN033 combined with standard chemotherapy, with or without another drug (bevacizumab), in people with advanced cervical cancer that has come back or spread. The goal is to see if the combination is safe and shrinks tumors. About 78 adults with…

This early-stage study tests a new drug called JSKN027 in 250 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study is done in two parts: first fin…

This study tests a new drug called JSKN033 in 160 people with advanced non-small cell lung cancer that cannot be cured. The goal is to see if the drug is safe and shrinks tumors. The trial has two parts: first finding the best dose, then testing it in more patients.